These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21197742)

  • 1. [Biology applied to cancer treatments: the example of colorectal cancer].
    Lièvre A; Laurent-Puig P
    Rev Prat; 2010 Oct; 60(8):1100-2. PubMed ID: 21197742
    [No Abstract]   [Full Text] [Related]  

  • 2. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
    Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
    J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
    [No Abstract]   [Full Text] [Related]  

  • 4. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
    Nozawa K; Watanabe T
    Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Loupakis F; Di Maio M; Falcone A
    N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
    [No Abstract]   [Full Text] [Related]  

  • 8. KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
    Lenz HJ; Chu E; Grothey A
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-13, 14-6. PubMed ID: 19378369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
    Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
    Cancer J; 2009; 15(2):110-3. PubMed ID: 19390304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.
    Silvestris N; Vincenzi B; Brunetti AE; Loupakis F; Dell'Aquila E; Russo A; Scartozzi M; Giampieri R; Cascinu S; Lorusso V; Tonini G; Falcone A; Santini D
    Pharmacogenomics; 2014 Sep; 15(13):1701-15. PubMed ID: 25410895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 13. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

  • 15. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
    McBride D
    ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
    [No Abstract]   [Full Text] [Related]  

  • 16. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 18. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
    Lièvre A; Laurent-Puig P
    Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
    Ariyama H; Kusaba H; Baba E
    Gan To Kagaku Ryoho; 2010 May; 37(5):782-6. PubMed ID: 20495306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the KRAS test.
    Laurent-Puig P; Lièvre A; Blons H
    Eur J Cancer; 2009 Sep; 45 Suppl 1():398-9. PubMed ID: 19775645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.